No Maintenance, Carfilzomib Maintenance, 1 prior line of therapy, Relapsed Refractory Multiple Myeloma (RRMM), Phase 2, Proteasome Inhibitors (PI)
### Instruction:
Identify the study with the following condition. 
### Input:
No Maintenance, Carfilzomib Maintenance, 1 prior line of therapy, Relapsed Refractory Multiple Myeloma (RRMM), Phase 2, Proteasome Inhibitors (PI) 
### Output:
Popular Name is MUK Five, Study ID is ISRCTN17354232